According to Ultragenyx's latest financial reports the company's current revenue (TTM) is $0.43 B. In 2022 the company made a revenue of $0.36 B an increase over the years 2021 revenue that were of $0.35 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.43 B | 19.52% |
2022 | $0.36 B | 3.39% |
2021 | $0.35 B | 29.66% |
2020 | $0.27 B | 161.32% |
2019 | $0.10 B | 101.41% |
2018 | $51.49 M | 1871.48% |
2017 | $2.61 M | 1863.91% |
2016 | $0.13 M | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Lexicon Pharmaceuticals
LXRX | $1.2 M | -99.72% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | $0.11 B | -73.21% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | $0.39 B | -8.04% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 457.11% | ๐บ๐ธ USA |